STE Stock Forecast 2025-2026
Distance to STE Price Targets
STE Price Momentum
10 Quality Stocks Worth Considering Now
Researching STERIS (STE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on STE and similar high-potential opportunities.
Latest STE Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, STE has a neutral consensus with a median price target of $263.00 (ranging from $230.00 to $265.00). The overall analyst rating is Buy (7.5/10). Currently trading at $222.23, the median forecast implies a 18.3% upside. This outlook is supported by 4 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Turkaly at JMP Securities, projecting a 19.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STE Analyst Ratings
STE Price Target Range
Latest STE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
| Apr 7, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 6, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $265.00 |
| Feb 6, 2025 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $240.00 |
| Feb 3, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $265.00 |
| Nov 18, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
| Nov 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Nov 7, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $260.00 |
| Oct 24, 2024 | Piper Sandler | Jason Bednar | Overweight | Upgrade | $260.00 |
| Sep 3, 2024 | Keybanc | Brett Fishbin | Overweight | Maintains | $265.00 |
| Aug 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Aug 7, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $260.00 |
| Aug 7, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
| Jul 26, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
| May 10, 2024 | Piper Sandler | Jason Bednar | Neutral | Reiterates | $225.00 |
| May 10, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| May 9, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
| Apr 12, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 9, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $250.00 |
| Feb 8, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
Steris plc (STE) Competitors
The following stocks are similar to STERIS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Steris plc (STE) Financial Data
Steris plc has a market capitalization of $21.83B with a P/E ratio of 35.7x. The company generates $5.40B in trailing twelve-month revenue with a 8.7% profit margin.
Revenue growth is +5.6% quarter-over-quarter, while maintaining an operating margin of +18.3% and return on equity of +9.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Steris plc (STE) Business Model
About Steris plc
Provides infection prevention and surgical products.
Steris generates revenue by offering a wide range of sterilization systems, surgical tables, and cleaning systems, along with essential support services like maintenance and training. The company primarily serves healthcare, pharmaceutical, and research sectors, ensuring sterile environments critical for patient safety and care efficiency.
Steris operates internationally and holds a strong position in the global medical devices market. Its solutions are vital for hospitals, outpatient surgery centers, and specialized laboratories, aligning with increasing healthcare demands and stringent regulatory standards.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
18,000
CEO
Mr. Daniel A. Carestio
Country
United States
IPO Year
1992
Website
www.steris.comSteris plc (STE) Latest News & Analysis
STE is gaining investor attention due to its robust Healthcare division and promising rebound potential in the AST segment.
STE's robust Healthcare performance and potential recovery in the AST segment indicate growth opportunities, making it an appealing investment prospect.
Steris upgraded to 'strong buy' with a $254 target. AST segment sees 9.5% growth; FY25 forecast is 6% revenue growth and 3.1% EPS growth, driven by Healthcare Products and AST.
Steris's 'strong buy' rating and projected growth in key segments signal potential for stock price appreciation, driven by recovery in AST and solid revenue forecasts, appealing to growth-focused investors.
Steris (STE) reported earnings 30 days ago; investors should monitor upcoming developments and performance indicators for future stock movements.
Earnings reports can influence stock performance and investor sentiment, guiding expectations for future growth and profitability, impacting STERIS's market valuation and investment decisions.
Steris' overseas revenue trends are influencing Wall Street's forecasts and the stock's outlook, indicating potential shifts in investor sentiment.
Steris' overseas revenue trends impact growth forecasts and stock valuation, influencing investor sentiment and potential returns. Changes in international performance can signal broader market opportunities or risks.
Steris has reduced its annual profit forecast due to the adverse effects of a stronger dollar.
Steris lowering its profit forecast indicates potential revenue challenges due to currency fluctuations, which could affect overall market performance and investor sentiment.
STERIS plc (STE) Q3 2025 Earnings Call Transcript
2 months agoSTERIS plc (NYSE:STE) will hold its Q3 2025 earnings conference call on February 6, 2025, at 9:00 AM ET, featuring key executives and industry analysts.
The STERIS Q3 2025 earnings call provides crucial insights into the company's financial performance and future outlook, influencing investor sentiment and stock valuation.
Frequently Asked Questions About STE Stock
What is Steris plc's (STE) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Steris plc (STE) has a median price target of $263.00. The highest price target is $265.00 and the lowest is $230.00.
Is STE stock a good investment in 2025?
According to current analyst ratings, STE has 4 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $222.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STE stock?
Wall Street analysts predict STE stock could reach $263.00 in the next 12 months. This represents a 18.3% increase from the current price of $222.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Steris plc's business model?
Steris generates revenue by offering a wide range of sterilization systems, surgical tables, and cleaning systems, along with essential support services like maintenance and training. The company primarily serves healthcare, pharmaceutical, and research sectors, ensuring sterile environments critical for patient safety and care efficiency.
What is the highest forecasted price for STE Steris plc?
The highest price target for STE is $265.00 from David Turkaly at JMP Securities, which represents a 19.2% increase from the current price of $222.23.
What is the lowest forecasted price for STE Steris plc?
The lowest price target for STE is $230.00 from at , which represents a 3.5% increase from the current price of $222.23.
What is the overall STE consensus from analysts for Steris plc?
The overall analyst consensus for STE is neutral. Out of 12 Wall Street analysts, 4 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $263.00.
How accurate are STE stock price projections?
Stock price projections, including those for Steris plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.